<SEC-DOCUMENT>0001714899-26-000070.txt : 20260522
<SEC-HEADER>0001714899-26-000070.hdr.sgml : 20260522
<ACCEPTANCE-DATETIME>20260521181745
ACCESSION NUMBER:		0001714899-26-000070
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20260521
ITEM INFORMATION:		Regulation FD Disclosure
FILED AS OF DATE:		20260522
DATE AS OF CHANGE:		20260521

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Denali Therapeutics Inc.
		CENTRAL INDEX KEY:			0001714899
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				463872213
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38311
		FILM NUMBER:		261010253

	BUSINESS ADDRESS:	
		STREET 1:		161 OYSTER POINT BLVD.
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		(650) 866-8547

	MAIL ADDRESS:	
		STREET 1:		161 OYSTER POINT BLVD.
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>dnli-20260521.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019e483c-0213-7247-8004-14df97cdc8e4,g:d7d82fe6-6bf8-4bd2-92f7-512bddf6f663,d:cd50f461145d40e6bbe5cceae1eb0f01-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>dnli-20260521</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-21">0001714899</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-22">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="dnli-20260521.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-05-21</xbrli:startDate><xbrli:endDate>2026-05-21</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="icd50f461145d40e6bbe5cceae1eb0f01_1"></div><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:20pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:20pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.785%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:20pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.785%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): </span></div><div style="margin-bottom:2pt;margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">May 21, 2026</ix:nonNumeric></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.785%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Denali Therapeutics Inc.</ix:nonNumeric></span></div><div style="margin-bottom:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.785%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.040%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.723%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.040%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.723%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.774%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-38311</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">46-3872213</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">incorporation)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File Number)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Identification No.)</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">161 Oyster Point Blvd.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">South San Francisco</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">California</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">94080</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices, including zip code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">650</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">866-8547</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable</span></div><div style="margin-bottom:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Former name or former address, if changed since last reports)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.785%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:2pt;text-align:center"><span><br/></span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:96.415%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.272%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.966%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Trading Symbol (s) </span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">DNLI</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8201;240.12b-2 of this chapter).</span></div><div style="margin-bottom:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:21.040%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.732%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:73.828%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-20">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    &#9744;</span></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.639%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="icd50f461145d40e6bbe5cceae1eb0f01_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;7.01 &#160;&#160;&#160;&#160;Regulation FD Disclosure.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 21, 2026, Denali Therapeutics Inc. (the &#8220;Company&#8221;) and Biogen Inc. issued a press release announcing topline results from the Phase 2b LUMA study evaluating BIIB122 (DNL151) in individuals with early-stage Parkinson&#8217;s disease.  A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8&#8209;K and is incorporated herein by reference.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in this Item 7.01 (including Exhibit 99.1) shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01&#160;&#160;&#160;&#160; Financial Statements and Exhibits.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)  Exhibits</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:70.855%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.164%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:83%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:83%">Description</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:83%">99.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="ex9912026pressrelease52126.htm">Press Release dated May 21, 2026</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:83%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Cover Page Interactive Data File (formatted as Inline XBRL)</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="icd50f461145d40e6bbe5cceae1eb0f01_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="text-align:justify;text-indent:37pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.747%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.993%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.124%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DENALI THERAPEUTICS INC.</span></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 21, 2026</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Ryan J. Watts</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ryan J. Watts, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex9912026pressrelease52126.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i44f6870fbd3b44cb8a1864b591977bcf_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">99.1</font></div></div><div><img alt="denali_greenlogo.jpg" src="denali_greenlogo.jpg" style="height:52px;margin-bottom:5pt;vertical-align:text-bottom;width:249px"></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:112%">Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson&#8217;s Disease</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.33pt">The Phase 2b LUMA study of BIIB122 in early-stage Parkinson&#8217;s disease did not meet its primary or secondary endpoints </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-style:italic;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.33pt">Based on data from the Phase 2b LUMA study, Biogen and Denali will discontinue development of BIIB122 in idiopathic Parkinson&#8217;s disease</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-style:italic;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.33pt">Denali continues to independently conduct the Phase 2a BEACON study in carriers of a pathogenic LRRK2 variant</font></div><div style="padding-left:36pt;text-indent:-18pt"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">CAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif., </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> May 21, 2026</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212; Biogen Inc. (Nasdaq&#58; BIIB) and Denali Therapeutics Inc. (Nasdaq&#58; DNLI) today announced topline results from the Phase 2b LUMA study evaluating BIIB122 (DNL151), an investigational small molecule inhibitor of LRRK2 (leucine-rich repeat kinase 2), in individuals with early-stage Parkinson&#8217;s disease. Results from the study show that BIIB122 did not slow the progression of Parkinson&#8217;s disease versus placebo, as measured by the primary endpoint of Time to Confirmed Worsening in the modified Movement Disorder Society Unified Parkinson&#8217;s Disease Rating Scale (MDS-UPDRS) Part II and III combined score. Secondary endpoints also did not show a benefit with BIIB122. Exploratory biomarker endpoints demonstrated &#62;90% kinase inhibition of peripheral LRRK2 (phosphoserine 935) and, in a cerebrospinal fluid (CSF) sub-study, up to approximately 30% reduction observed in a biomarker of LRRK2 activity (phosphorylated Rab10). Expected levels of BIIB122 in the blood and CSF were sustained across the study. BIIB122 was generally well tolerated with an acceptable safety profile. Based on these results, Biogen and Denali will discontinue further development of BIIB122 in idiopathic Parkinson&#8217;s disease. Denali will continue to independently conduct the Phase 2a BEACON study evaluating the small molecule inhibitor in carriers of a pathogenic LRRK2 variant.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font></div><div id="i44f6870fbd3b44cb8a1864b591977bcf_4"></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;While these are not the results we hoped for, these data provide important information to the Parkinson&#8217;s community and will be presented at an upcoming scientific conference,&#8221; said Diana Gallagher, MD, Senior Vice President and Head of Neurodegeneration Clinical Development at Biogen. &#8220;We are profoundly grateful to the patients, families, and investigators who participated in this study and contributed to our understanding of Parkinson&#8217;s disease.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">LUMA was a Phase 2b multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of BIIB122 compared to placebo in 648 people with early-stage Parkinson&#8217;s disease between the ages of 30 and 80. Participants received BIIB122 or placebo for a minimum of 48 weeks and up to 144 weeks. The study included individuals with early-stage Parkinson&#8217;s disease with or without a pathogenic LRRK2 variant. The LUMA study was designed to evaluate the potential of LRRK2 inhibition to address the underlying biology of Parkinson&#8217;s disease. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;While we are disappointed with these results, we believe the LUMA study was a robust test of LRRK2 inhibition using BIIB122 in idiopathic Parkinson&#8217;s disease and there is more to be learned about LRRK2 as a potential therapeutic target,&#8221; said Peter Chin, M.D., Chief Medical Officer and Head of Development of Denali Therapeutics. &#8220;Independently, we continue to study this small molecule inhibitor in the Phase 2a BEACON study in individuals with Parkinson&#8217;s disease who are confirmed by genetic testing to be carriers of a pathogenic LRRK2 variant, which is associated with increased LRRK2 kinase activity. We look forward to further analysis of the LUMA data and the results from BEACON to inform next steps for development.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The global Phase 2a BEACON study is designed</font><font style="color:#3a7c22;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">to assess safety, pharmacokinetics and biomarkers of lysosomal pathway engagement, which will inform the biomarker profile in LRRK2 pathogenic variant carriers and the impact of LRRK2 inhibition. Data from the BEACON study is anticipated in the first half of 2027. The BEACON study is being operationalized by Denali and funded under a Collaboration and Development Funding Agreement between Denali and a third party.</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Biogen and Denali will share detailed findings from the LUMA study at an upcoming scientific conference to contribute to the broader understanding of Parkinson&#8217;s disease and LRRK2 biology.</font></div><div id="i44f6870fbd3b44cb8a1864b591977bcf_7"></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">About Parkinson&#8217;s Disease</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Parkinson&#8217;s disease is a progressive neurodegenerative disorder that affects movement and a wide range of non-motor functions. It is characterized by motor symptoms such as tremor, muscle stiffness, slowness of movement, and balance difficulty, as well as non-motor symptoms including sleep disturbances, mood changes, and cognitive impairment. One million people in the U.S. and more than 10 million people worldwide are estimated to have Parkinson&#8217;s disease. Parkinson&#8217;s disease is especially difficult to develop drugs for because of its complexity, with patients presenting differently and responding variably to treatment. The lack of reliable biomarkers, along with diverse and often unknown biological causes of the disease, also makes it challenging to track disease progression in clinical trials.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">About LRRK2</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Following discovery of the LRRK2 (leucine-rich repeat kinase 2) mutation as a pathogenic genetic factor for Parkinson&#8217;s disease, further research has uncovered that it has the potential to be a novel therapeutic target for Parkinson&#8217;s disease. Mutations in LRRK2 account for 4-5% of familial and 1-2% of sporadic Parkinson&#8217;s disease.1, 2 In addition, common variants in and around LRRK2 have been identified as risk factors for sporadic Parkinson&#8217;s disease.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">While the exact pathogenic mechanisms remain unknown, LRRK2 is believed to play a role in intracellular trafficking in the endolysosomal system, and the endolysosomal system is overrepresented among rare and common risk gene variants for Parkinson&#8217;s disease.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">3,4,5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Lysosomal dysfunction is a central pathogenic driver of Parkinson&#8217;s disease, characterized by failure of the cell&#8217;s waste disposal system (lysosomes) to break down proteins, which then accumulate and create aggregates that can cause neuronal degeneration.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">About Biogen</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients&#8217; lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth. We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media - Facebook, Instagram, LinkedIn, X, YouTube.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">About Denali Therapeutics </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Denali Therapeutics Inc. is a biotechnology company pioneering a new class of biotherapeutics designed to cross the blood-brain barrier using its proprietary TransportVehicle&#8482; platform. With a clinically validated delivery platform and a growing portfolio of therapeutic candidates across all stages of development, Denali is advancing toward its goal of delivering effective medicines to transform life for people with neurodegenerative diseases, lysosomal storage disorders and other serious diseases. For more information, please visit www.denalitherapeutics.com.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Biogen Safe Harbor</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This press release contains forward-looking statements including, among others, relating to the potential benefits and results that may be achieved through Biogen&#8217;s collaboration with Denali&#59; our efforts to contribute to and advance the understanding of Parkinson&#8217;s disease&#59; the clinical development program, clinical trials, data readouts and presentations related to BIIB122&#59; the treatment of Parkinson&#8217;s disease and the relation between LRRK2 biology and Parkinson&#8217;s disease&#59; the potential of Biogen&#8217;s commercial business and pipeline programs&#59; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by words such as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;possible,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or the scientific data presented. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:124%">These forward-looking statements are based on management&#8217;s current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to differ materially from those stated or implied in this document, including, among others, uncertainty of our long-term </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:124%">success in developing, licensing, or acquiring other product candidates or additional indications for existing products&#59; expectations, plans, prospects and timing of actions relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products&#59; the potential impact of increased product competition in the biopharmaceutical and healthcare industry, as well as any other markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways&#59; our ability to effectively implement our corporate strategy&#59; difficulties in obtaining and maintaining adequate coverage, pricing, and reimbursement for our products&#59; the drivers for growing our business, including our dependence on collaborators and other third parties for the development, regulatory approval, and commercialization of products and other aspects of our business, which are outside of our full control&#59; risks related to commercialization of biosimilars, which is subject to such risks related to our reliance on third-parties, intellectual property, competitive and market challenges and regulatory compliance&#59; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications&#59; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates&#59; and the occurrence of adverse safety events, restrictions on use with our products, or product liability claims&#59; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission, which are available on the SEC&#8217;s website at www.sec.gov. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:124%">These statements speak only as of the date of this press release and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and in our subsequent reports on Form 10-Q. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Digital Media Disclosure</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">From time to time we have used, or expect in the future to use, our investor relations website (investors.biogen.com), the Biogen LinkedIn account (linkedin.com&#47;company&#47;biogen-) and the Biogen X account (https&#58;&#47;&#47;x.com&#47;biogen) as a means of disclosing information to the public in a broad, non-exclusionary manner, including for purposes of the SEC&#8217;s Regulation Fair Disclosure (Reg FD). Accordingly, investors should monitor our investor relations website and this social media channel in addition to our press releases, SEC filings, public conference calls and webcasts, as the information posted on them could be material to investors.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Denali Safe Harbor</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements by Denali Therapeutics Inc. (&#8220;Denali&#8221; or the &#8220;Company&#34;) regarding plans, timelines and expectations related to the ongoing Phase 2a BEACON study of BIIB122 in LRRK2-associated Parkinson's disease, including the timing and availability of clinical data&#59; the presentation of data related to the Phase 2b LUMA study&#59; the discontinuation of development of DNL151 in idiopathic Parkinson&#8217;s disease&#59; the continued evaluation of DNL151 based on its safety profile&#59; the potential of LRRK2 as a therapeutic target&#59; Denali&#8217;s plans to share detailed findings from the LUMA study at an upcoming scientific conference&#59; and statements by Denali's Chief Medical Officer and Head of Development. Actual results may differ materially from those expressed or implied by these forward-looking statements due to a variety of risks and uncertainties. These include, but are not limited to, uncertainties related to the FDA&#8217;s policies&#59; risks arising from adverse economic conditions and their impact on Denali&#8217;s business and operations&#59; the possibility of events or changes that could lead to the termination of Denali&#8217;s collaboration agreements&#59; challenges associated with Denali&#8217;s transition to a commercial company&#59; the ability of Denali and its collaborators to complete the development and, if approved, the commercialization of product candidates&#59; difficulties in patient enrollment for ongoing and future clinical trials&#59; reliance on third-party manufacturers and suppliers for clinical trial materials&#59; potential delays or failures in meeting expected clinical trial timelines&#59; discrepancies between preclinical, early-stage or preliminary clinical results and outcomes from later-stage trials&#59; the risk that interim or topline clinical results may not be predictive of final study results or longer&#8209;term outcomes&#59; the occurrence of significant adverse events or other undesirable side effects&#59; the uncertainty surrounding regulatory approvals required for commercialization in the U.S., Europe or other international jurisdictions&#59; Denali&#8217;s ability to advance a pipeline of product candidates or develop commercially successful products&#59; developments relating to Denali's </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">competitors and competing product candidates&#59; Denali&#8217;s ability to obtain, maintain or protect intellectual property rights related to its product candidates&#59; the implementation and success of Denali&#8217;s strategic plans for its business, product candidates and blood-brain barrier platform technology&#59; Denali's ability to obtain additional capital to finance its operations, as needed&#59; Denali's ability to accurately forecast future financial results in the current environment&#59; and other risks and uncertainties, including those described in Denali's most recent Annual and Quarterly Reports on Forms 10-K and 10-Q filed with the Securities and Exchange Commission (SEC) on February 26, 2026 and May 7, 2026, respectively, and Denali&#8217;s future reports to be filed with the SEC. Except for AVLAYAH&#8482; (tividenofusp alfa-eknm), Denali's product candidates are investigational, and their safety and efficacy profiles have not yet been established. Denali does not undertake any obligation to update or revise any forward-looking statements, to conform these statements to actual results or to make changes in Denali&#8217;s expectations, except as required by law.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">References&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13pt">Healy DG, Falchi M, O'Sullivan SS, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease&#58; a case-control study. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Lancet Neurol</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. 2008&#59;7(7)&#58;583-90.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13pt">Hernandez DG, Reed X, Singleton AB. Genetics in Parkinson disease&#58; Mendelian versus non-Mendelian inheritance. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">J Neurochem</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. 2016&#59;139 Suppl 1&#58;59-74. Epub 2016&#47;04&#47;18.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13pt">Bonet-Ponce, Luis et al. &#8220;LRRK2 mediates tubulation and vesicle sorting from lysosomes.&#8221; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Science advances</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> vol. 6,46 eabb2454. 11 Nov. 2020, doi&#58;10.1126&#47;sciadv.abb2454</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13pt">Robak, Laurie A et al. &#8220;Excessive burden of lysosomal storage disorder gene variants in Parkinson's disease.&#8221; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Brain &#58; a journal of neurology</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> vol. 140,12 (2017)&#58; 3191-3203. doi&#58;10.1093&#47;brain&#47;awx285</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13pt">Smolders, Stefanie, and Christine Van Broeckhoven. &#8220;Genetic perspective on the synergistic connection between vesicular transport, lysosomal and mitochondrial pathways associated with Parkinson's disease pathogenesis.&#8221; Acta neuropathologica communications vol. 8,1 63. 6 May. 2020, doi&#58;10.1186&#47;s40478-020-00935-4</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13pt">Moors, Tim et al. &#8220;Lysosomal Dysfunction and &#945;-Synuclein Aggregation in Parkinson's Disease&#58; Diagnostic Links.&#8221; Movement disorders &#58; official journal of the Movement Disorder Society vol. 31,6 (2016)&#58; 791-801. doi&#58;10.1002&#47;mds.26562</font></div><div style="padding-left:144pt;text-indent:36pt"><font><br></font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">     </font></div><div style="margin-top:10pt"><font><br></font></div><div id="i44f6870fbd3b44cb8a1864b591977bcf_10"></div><div><font><br></font></div><div style="margin-top:10pt"><font><br></font></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"></td><td style="width:19.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.907%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.109%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">###</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MEDIA CONTACT&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INVESTOR CONTACT&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Biogen</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Biogen</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Madeleine Shin</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tim Power</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+1-781-464-3260</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+1 781 464 2442</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">public.affairs&#64;biogen.com</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IR&#64;biogen.com</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denali Therapeutics</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denali Therapeutics</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Erin Patton</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laura Hansen, Ph.D.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">epatton&#64;dnli.com</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">hansen&#64;dnli.com</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>dnli-20260521.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019e483c-0213-7247-8004-14df97cdc8e4,g:d7d82fe6-6bf8-4bd2-92f7-512bddf6f663-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dnli="http://www.denalitherapeutics.com/20260521" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.denalitherapeutics.com/20260521">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dnli-20260521_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dnli-20260521_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.denalitherapeutics.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>dnli-20260521_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019e483c-0213-7247-8004-14df97cdc8e4,g:d7d82fe6-6bf8-4bd2-92f7-512bddf6f663-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SolicitingMaterial_019e483c-0213-759b-818a-b3998fe751d2_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_019e483c-0213-7a1a-a2db-41ca37f9af42_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_019e483c-0213-7dee-ab9f-c4b584266ce5_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_019e483c-0213-7a62-b537-5419bd905aac_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_019e483c-0213-7a7e-9248-2fad265f95d1_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_019e483c-0213-7578-8c9b-1a866a567cd9_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_019e483c-0213-70a7-a6dd-85230b3aa72f_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_019e483c-0213-72de-bfe9-a36bf702a9f3_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_019e483c-0213-725b-bda0-c1f734e77997_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_019e483c-0213-704d-8703-5c67cdb1a827_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_019e483c-0213-7ef2-9ad9-9627494a5034_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_019e483c-0213-7c0f-9569-e09a5108d964_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_019e483c-0213-7b56-b78b-19c01a501caa_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_019e483c-0213-717f-b4f5-24fc00951a17_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_019e483c-0213-7cd1-bdb1-a3dad8ed2cab_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_019e483c-0213-717c-b137-3f6509e06d38_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_019e483c-0213-7e91-8136-56b184b6facb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_019e483c-0213-72ef-8895-daf55d128b42_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_019e483c-0213-7b7f-9cc2-31f11021126b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_019e483c-0213-7c26-aebe-22539e8e6f7e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_019e483c-0213-75ea-9104-00b84eb66486_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_019e483c-0213-7de2-a955-d963cf7e3245_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>dnli-20260521_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019e483c-0213-7247-8004-14df97cdc8e4,g:d7d82fe6-6bf8-4bd2-92f7-512bddf6f663-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/Cover" xlink:type="simple" xlink:href="dnli-20260521.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_019e483c-0213-70b9-901a-e4e8ba992c45" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_019e483c-0213-78cd-ac05-dd838287091d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e483c-0213-70b9-901a-e4e8ba992c45" xlink:to="loc_dei_DocumentType_019e483c-0213-78cd-ac05-dd838287091d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_019e483c-0213-7e0e-96cb-25d23745ef7f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e483c-0213-70b9-901a-e4e8ba992c45" xlink:to="loc_dei_DocumentPeriodEndDate_019e483c-0213-7e0e-96cb-25d23745ef7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_019e483c-0213-7e8c-bc3d-700816b4897b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e483c-0213-70b9-901a-e4e8ba992c45" xlink:to="loc_dei_EntityRegistrantName_019e483c-0213-7e8c-bc3d-700816b4897b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_019e483c-0213-7476-86cb-df086f5215c0" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e483c-0213-70b9-901a-e4e8ba992c45" xlink:to="loc_dei_EntityIncorporationStateCountryCode_019e483c-0213-7476-86cb-df086f5215c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_019e483c-0213-7018-b89e-7cff0b345426" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e483c-0213-70b9-901a-e4e8ba992c45" xlink:to="loc_dei_EntityFileNumber_019e483c-0213-7018-b89e-7cff0b345426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_019e483c-0213-726f-b3fb-1af47c695dad" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e483c-0213-70b9-901a-e4e8ba992c45" xlink:to="loc_dei_EntityTaxIdentificationNumber_019e483c-0213-726f-b3fb-1af47c695dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_019e483c-0213-7460-ae5d-dc091f3a60ee" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e483c-0213-70b9-901a-e4e8ba992c45" xlink:to="loc_dei_EntityAddressAddressLine1_019e483c-0213-7460-ae5d-dc091f3a60ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_019e483c-0213-731e-97cb-b59564665fbd" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e483c-0213-70b9-901a-e4e8ba992c45" xlink:to="loc_dei_EntityAddressCityOrTown_019e483c-0213-731e-97cb-b59564665fbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_019e483c-0213-7faf-ace9-0533bb17a03e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e483c-0213-70b9-901a-e4e8ba992c45" xlink:to="loc_dei_EntityAddressStateOrProvince_019e483c-0213-7faf-ace9-0533bb17a03e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_019e483c-0213-7fca-8946-20a475714d7d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e483c-0213-70b9-901a-e4e8ba992c45" xlink:to="loc_dei_EntityAddressPostalZipCode_019e483c-0213-7fca-8946-20a475714d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_019e483c-0213-70a6-a579-a37a3f800261" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e483c-0213-70b9-901a-e4e8ba992c45" xlink:to="loc_dei_CityAreaCode_019e483c-0213-70a6-a579-a37a3f800261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_019e483c-0213-7986-973b-40d9e37142d2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e483c-0213-70b9-901a-e4e8ba992c45" xlink:to="loc_dei_LocalPhoneNumber_019e483c-0213-7986-973b-40d9e37142d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_019e483c-0213-7fc2-ac22-0ba51ec6eed8" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e483c-0213-70b9-901a-e4e8ba992c45" xlink:to="loc_dei_WrittenCommunications_019e483c-0213-7fc2-ac22-0ba51ec6eed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_019e483c-0213-7213-b0da-0a0d5c71b6b7" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e483c-0213-70b9-901a-e4e8ba992c45" xlink:to="loc_dei_SolicitingMaterial_019e483c-0213-7213-b0da-0a0d5c71b6b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_019e483c-0213-70ad-b19b-99a6e2ee8ace" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e483c-0213-70b9-901a-e4e8ba992c45" xlink:to="loc_dei_PreCommencementTenderOffer_019e483c-0213-70ad-b19b-99a6e2ee8ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_019e483c-0213-798c-8e06-b8e15e9845da" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e483c-0213-70b9-901a-e4e8ba992c45" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_019e483c-0213-798c-8e06-b8e15e9845da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_019e483c-0213-7e8b-a61b-1becdfc26631" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e483c-0213-70b9-901a-e4e8ba992c45" xlink:to="loc_dei_EntityEmergingGrowthCompany_019e483c-0213-7e8b-a61b-1becdfc26631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_019e483c-0213-767e-9c18-0a192f97a46a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e483c-0213-70b9-901a-e4e8ba992c45" xlink:to="loc_dei_TradingSymbol_019e483c-0213-767e-9c18-0a192f97a46a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_019e483c-0213-7b8f-a108-c1bc312ddc1b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e483c-0213-70b9-901a-e4e8ba992c45" xlink:to="loc_dei_SecurityExchangeName_019e483c-0213-7b8f-a108-c1bc312ddc1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_019e483c-0213-73ea-be11-e41af218c915" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e483c-0213-70b9-901a-e4e8ba992c45" xlink:to="loc_dei_EntityCentralIndexKey_019e483c-0213-73ea-be11-e41af218c915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_019e483c-0213-733e-a92a-08467e3ffbb4" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e483c-0213-70b9-901a-e4e8ba992c45" xlink:to="loc_dei_AmendmentFlag_019e483c-0213-733e-a92a-08467e3ffbb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_019e483c-0213-7cab-b15c-2c069e5816e6" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019e483c-0213-70b9-901a-e4e8ba992c45" xlink:to="loc_dei_Security12bTitle_019e483c-0213-7cab-b15c-2c069e5816e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>denali_greenlogo.jpg
<TEXT>
begin 644 denali_greenlogo.jpg
M_]C_X  02D9)1@ ! @$ 2 !(  #_X@_P24-#7U!23T9)3$4  0$   _@87!P
M; (0  !M;G1R4D="(%A96B 'Z0 +  0 !P 5 #AA8W-P05!03     !!4%!,
M                        ]M8  0    #3+6%P<&P
M                                             !%D97-C   !4
M &)D<V-M   !M   !+QC<')T   &<    "-W='!T   &E    !1R6%E:   &
MJ    !1G6%E:   &O    !1B6%E:   &T    !1R5%)#   &Y   " QA87)G
M   .\    "!V8V=T   /$    #!N9&EN   /0    #YM;6]D   /@    "AV
M8V=P   /J    #AB5%)#   &Y   " QG5%)#   &Y   " QA86)G   .\
M "!A86=G   .\    "!D97-C          A$:7-P;&%Y
M
M                                ;6QU8P         G    #&AR2%(
M   4   !Y&MO2U(    ,   !^&YB3D\    2   "!&ED       2   "%FAU
M2%4    4   "*&-S0UH    6   "/'-L4TD    4   "4F1A1$L    <   "
M9FYL3DP    6   "@F9I1DD    0   "F&ET250    8   "J&5S15,    6
M   "P')O4D\    2   "UF9R0T$    6   "Z&%R       4   "_G5K54$
M   <   #$FAE24P    6   #+GIH5%<    *   #1'9I5DX    .   #3G-K
M4TL    6   #7'IH0TX    *   #1')U4E4    D   #<F5N1T(    4   #
MEF9R1E(    6   #JFUS       2   #P&AI24X    2   #TG1H5$@    ,
M   #Y&-A15,    8   #\&5N054    4   #EF5S6$P    2   "UF1E1$4
M   0   $"&5N55,    2   $&'!T0E(    8   $*G!L4$P    2   $0F5L
M1U(    B   $5'-V4T4    0   $=G1R5%(    4   $AG!T4%0    6   $
MFFIA2E     ,   $L !, $, 1  @ '4 ( !B &\ :@!ISNRW[  @ $P 0P!$
M $8 80!R &< 90 M $P 0P!$ $P 0P!$ "  5P!A '( ;@!A %, >@#M &X
M90!S "  3 !# $0 0@!A '( 90!V &X _0 @ $P 0P!$ $( 80!R '8 ;@!I
M "  3 !# $0 3 !# $0 +0!F &$ <@!V &4 <P!K .8 <@!M $L ; !E '4
M<@!E &X +0!, $, 1 !6 .0 <@!I "T 3 !# $0 3 !# $0 ( !A "  8P!O
M &P ;P!R &D 3 !# $0 ( !A "  8P!O &P ;P!R $P 0P!$ "  8P!O &P
M;P!R $$ 0P!, "  8P!O '4 ; !E '4 <B / $P 0P!$ " &109$!D@&1@8I
M!!H$/@0[!$P$/@1 !#X$,@0X!#D ( !, $, 1" / $P 0P!$ " %Y@71!>(%
MU07@!=E?:8)R $P 0P!$ $P 0P!$ "  30#@ '4 1@!A '( 90!B &X _0 @
M $P 0P!$!"8$,@0U!$($/00^!#D ( 06!!H +00T!#@$000_!#L$-00Y $,
M;P!L &\ =0!R "  3 !# $0 3 !# $0 ( !C &\ =0!L &4 =0!R %< 80!R
M &X 80 @ $P 0P!$"3 ) @D7"4 )*  @ $P 0P!$ $P 0P!$ " .*@XU $P
M0P!$ "  90!N "  8P!O &P ;P!R $8 80!R &( +0!, $, 1 !# &\ ; !O
M '( ( !, $, 1 !, $, 1  @ $, ;P!L &\ <@!I &0 ;P!+ &\ ; !O '(
M( !, $, 1 .( [,#QP/! \D#O .W " #OP.X \P#O0.W "  3 !# $0 1@#D
M '( 9P M $P 0P!$ %( 90!N &L ; !I "  3 !# $0 3 !# $0 ( !A "
M8P!O '( 90!S,*LPZ3#\ $P 0P!$=&5X=     !#;W!Y<FEG:'0@07!P;&4@
M26YC+BP@,C R-0  6%E:(        /-1  $    !%LQ865H@        @]\
M #V_____NUA96B        !*OP  L3<   JY6%E:(        "@X   1"P
MR+EC=7)V        !      %  H #P 4 !D '@ C "@ +0 R #8 .P!  $4
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MWO9M]OOWBO@9^*CY./G'^E?ZY_MW_ ?\F/TI_;K^2_[<_VW__W!A<F$
M  ,    "9F8  /*G   -60  $]    I;=F-G=          !  $
M 0    $          0    $          0  ;F1I;@         V  "N%
M4>P  $/7  "PI   )F8   ]<  !0#0  5#D  C,S  (S,P ",S,
M &UM;V0        &$   H%+]8FUB                          !V8V=P
M       #     F9F  ,    "9F8  P    )F9@    (S,S0      C,S-
M   ",S,T /_N  Y!9&]B90!D      '_VP!#  P("!L*&R(1%R0J)!P;("0K
M*"@@)"DE)3$O)2DN*BLK.2LJ+B\T-34U-"\[.SL[.SL[.SL[.SL[.SL[.SL[
M.SO_VP!# 0T+"Q .$!L4&R0R*"$H,CLT,C(R.SL[.SL[.SL[.SL[.SL[.SM
M0$! 0#M 0$! 0$! 0$! 0$! 0$! 0$! 0$#_VP!# @T+"Q .$!L4&R0R*"$H
M,CLT,C(R.SL[.SL[.SL[.SL[.SL[.SM 0$! 0#M 0$! 0$! 0$! 0$! 0$!
M0$! 0$#_P  1" '%"&$# "(  1$! A$"_\0 'P   04! 0$! 0$
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M]?;W^/GZ_]H # ,   $1 A$ /P#U6BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** *UY?+9H99"%5>I-<M<?$J-#A(V(]20O^-9/Q#U RRBW_
M (8P#^)Y_D17)XII$2EJ=]_PLU?^>1_[['^%'_"S5_YY'_OL?X5P.*,4[$\[
M.^_X6:O_ #R/_?8_PH_X6:O_ #R/_?8_PK@<48HL'.SOO^%FK_SR/_?8_P *
M=%\3(R<-&P^A!_F!7G^* <46#G9Z_I7B2'4^(V^;^Z>&_+_#BM/=7A\<AB(9
M205Z$=1^->E^#_$G]JJ8Y/\ 6IU]QG@_X_\ UZ31:D=/1112*"BBB@ HHHH
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MZ8'->&X[UV?AOQT8BL%R<@]'[\],TFBXR/0:*8K[N1SGTI](L**** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8/CD9LY?\
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MZ:BBBD6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 >>_$S_61_[A_G7&UV7Q,_UD?^X?YUQM4C.6X4444$A1110 44
M44 =!X$_X^T^C_\ H)KU.O+/ G_'VGT?_P!!->IU+-(;"T444%!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !6#XX_X\Y?^ ?^AK6]6#XX_P"/.7_@'_H:
MT">QY2:*#13,@HHHI@%%%% !6[X'_P"/R+_@?_H#5A5N^!_^/R+_ ('_ .@-
M0-;GJ]%%%2:GA=%2W=N;9VB;JI(_*HJHQ"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
M4\.:N=*F67/RG ;Z'K6710&Q[DK9Y[4ZN=\%ZG]NMU!^]&=I_#!'Z'^==%4F
MR=PHHHH **** "BBB@ HHHH **** "BBB@ I*6J]]="T1I6Z(I/Y4 <'\0=:
M\YQ:+T09;ZD9 _ ?SKCS4MS<M<,TK'YF))_$YJ*J,I.["BBB@04444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !0!10#0!ZYX0_P"/2+_=_J:V*R_#,!@MHD;J$'Z\_P!:U*DV"BBB@ HH
MHH **** "BBB@ HHHH **** $-8OBG5_[,@9Q]YOE7ZGO^%;5>:_$#4OM$X@
M!XB X[9/)_2@3=CEV)8DGO24451D%%%% !1110 4444 %%%% !1110 4444
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M&O7:Y?QYI/VR#S5'S1<_\![C\.OX4)DR5SS2BC&>:*HS"BBB@ HHHH ****
M.@\$ZO\ 8)PK'Y9?E/L>@/Y\?2O4LFO#@V.1UKUOPSJW]IP++_$!AOJO^-)E
MP9L4444BPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** //?B9_K(_]P_SKC:[+XF?ZR/_ '#_ #KC:I&<MPHHHH)"BBB@ HHH
MH Z#P)_Q]I]'_P#037J=>6>!/^/M/H__ *":]3J6:0V%HHHH*"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "L'QQ_QYR_\ _\ 0UK>K!\<?\><O_ /_0UH
M$]CRDT4&BF9!1113 **** "MWP/_ ,?D7_ __0&K"K=\#_\ 'Y%_P/\ ] :@
M:W/5Z***DU$Q12T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ"TF7 6BEHI%B44M% "44M% "44M% "44M% "44M% "44M% "44M% "44M%
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M *":]3J6:0V%HHHH*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L'QQ_Q
MYR_\ _\ 0UK>K!\<?\><O_ /_0UH$]CRDT4&BF9!1113 **** "MWP/_ ,?D
M7_ __0&K"K=\#_\ 'Y%_P/\ ] :@:W/5Z***DU"BBB@ HHHH **** "BBB@
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M *&M;U8/CC_CSE_X!_Z&M GL>4FB@T4S(****8!1110 5N^!_P#C\B_X'_Z
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M% 'J_@?_ (\XO^!_^AM6[6%X'_X\XO\ @?\ Z&U;M2;(**** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHHH **** "BBB@#B/B9TB_X'_-*X*N]^)G2+_@?\TK@JI&<MPHHHH)"BBB@
MHHHH LZ9_K8_]]?YBO:A7BNF?ZV/_?7^8KVH4F7 6BBBD6%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 )1110!X=+U/UIM.EZGZTVJ,0HH
MHH **** "BBB@#U?P/\ \><7_ __ $-JW:PO _\ QYQ?\#_]#:MVI-D%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 )FH9[D0*7/0"I<5S_
M (EN\8A'KDU$Y\JN72ASR43"GE,Q+'JQIE%%>>]3UTK"T444AA1110 4444
M)6OX<L_-<R'HO\SR/TK(Q7::79_98PO?'/UK:A3O*YRXNKRPY>I=Q1BEHKN/
M."BBB@ HHHH **** ,CQ)I7]IP-%_%U7ZC_ZV1]#7D9&#C_/TKW'%>7^.=(^
MPS[U^[*"P] 1]X4T1-'.T444R HHHH **** "C-%% 'I7@+5_M</D-]Z+ _X
M"?N_ETKJ<UY#X9U;^S)UD)^4\-]#_AQ^5>N@YI,UB[H=1112&%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!Y[\3/]9'_N'^=<;79?$S_61_[A_G
M7&U2,Y;A11102%%%% !1110!T'@3_C[3Z/\ ^@FO4Z\L\"?\?:?1_P#T$UZG
M4LTAL+11104%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8/CC_CSE_P"
M?^AK6]6#XX_X\Y?^ ?\ H:T">QY2:*#13,@HHHI@%%%% !6[X'_X_(O^!_\
MH#5A5N^!_P#C\B_X'_Z U UN>KT445)J%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Q?Q+_ -7%_OG^
M5>?UZ!\2_P#5Q?[Y_E7G]4C.>X4444$A1110 4444 /M_O+]1_.O<:\.M_O+
M]1_.O<:3+AL%%%%(L**** "BBB@ HHHH **** "BBB@ KRKQU_Q]R?1/_0!7
MJM>5>.O^/N3Z)_Z *:)GL8%%%%,S"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /2?AS_Q[-_UU
M;_T%:ZH5ROPY_P"/9O\ KJW_ *"M=4*DU0M%%% PHHHH **** "BBB@ HHHH
M **** "BBB@#B/B9TB_X'_-*X*N]^)G2+_@?\TK@JI&<MPHHHH)"BBB@ HHH
MH LZ9_K8_P#?7^8KVH5XKIG^MC_WU_F*]J%)EP%HHHI%A1110 4444 %%%%
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M_4?SKW&DRX;!1112+"BBB@ HHHH **** "BBB@ HHHH *\J\=?\ 'W)]$_\
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M1>3_ $K/S^M=;H-G]G3/=L&M*$.>1SXFIR0OU9J[:,4M%>@>8%%%% !1110
M4444 %%%% !1110!S?C;2/[0@+*/GB^8>X[C\N:\OKW$IGBO(_$VE'3)VB'W
M2=R_[I_PIHB:,JBBBF0%%%% !1110 4444 >L>$]7_M.!7/WD^5OJ!U_$5MU
MY=X'U?[#/L8_)+\OT;L?YC\:]0-)FJ=T.HHHI#"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#SWXF?ZR/_</\ZXVNR^)G^LC_ -P_SKC:I&<MPHHHH)"B
MBB@ HHHH Z#P)_Q]I]'_ /037J=>6>!/^/M/H_\ Z":]3J6:0V%HHHH*"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+%'^Q(/^>2?]\+_A1_8D'_/)/^^%_P *O44!8H_V)!_SR3_OA?\ "C^Q(/\
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M0 4444 6=,_UL?\ OK_,5[4*\5TS_6Q_[Z_S%>U"DRX"T444BPHHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+/ G_'VGT?\ ]!->IU+-(;"T444%!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !6#XX_X\Y?\ @'_H:UO5@^./^/.7_@'_ *&M GL>4FB@T4S(****8!11
M10 5N^!_^/R+_@?_ * U85;O@?\ X_(O^!_^@-0-;GJ]%%%2:A1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 <7\2_P#5Q?[Y_E7G]>@?$O\ U<7^^?Y5Y_51,Y[A11102%%%% !1110
M^W^\OU'\Z]QKPZW^\OU'\Z]QI,N&P4444BPHHHH **** "BBB@ HHHH ****
M "O*O'7_ !]R?1/_ $ 5ZK7E7CK_ (^Y/HG_ * *:)GL8%%%%,S"BBB@ HHH
MH *[+X:?ZR3_ '!_.N-KLOAI_K)/]P?SH8X[GH-+24M2:A1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M37J=>6>!/^/M/H__ *":]3J6:0V%HHHH*"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "L'QQ_QYR_\ _\ 0UK>K!\<?\><O_ /_0UH$]CRDT4&BF9!1113
M **** "MWP/_ ,?D7_ __0&K"K=\#_\ 'Y%_P/\ ] :@:W/5Z***DU"BBB@
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M_/1_^^C_ (T?VE+_ ,]'_P"^C_C187.>TYHS7BW]I2_\]'_[Z/\ C1_:4O\
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M?^ C=7KM>>_#>QW.\YZ*H4?5N3^@_6O0J3-(+0****104444 %%%% !1110
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MX$RAUY##(/L1FO$?>O1/A]JOGQ&V)^:(\?[I_P #^F*&BX,["BBBI+"BBB@
MHHHH **** "BBB@ HHHH Y'XCVQD@60?P.,_0@C^>*\YKV'Q%8_;H)(NY7CZ
MCD5X]FFC.>X4444R0HHHH **** #ISWKIO"OB_\ LL>1+S'G@\Y7\.XKF:*
M3LSVFPU..^7?$P8>W]1VJSFO#T<QG*G!'IQ4W]I2_P!]O^^C_C2L7SGM6:,U
MXM_:4O\ ST?_ +Z/^-']I2_\]'_[Z/\ C18.<]IS1FO%O[2E_P">C_\ ?1_Q
MH_M*7_GH_P#WT?\ &BP<Y[3FC->+?VE+_P ]'_[Z/^-']I2_\]'_ .^C_C18
M.<]IS1FO%O[2E_YZ/_WT?\:/[2E_YZ/_ -]'_&BP<Y[3FC->+?VE+_ST?_OH
M_P"-']I2_P#/1_\ OH_XT6#G/:<T9KQ;^TI?^>C_ /?1_P :/[2E_P">C_\
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M4 %8/CC_ (\Y?^ ?^AK6]6#XX_X\Y?\ @'_H:T">QY2:*#13,@HHHI@%%%%
M!6[X'_X_(O\ @?\ Z U85;O@?_C\B_X'_P"@-0-;GJ]%%%2:GALDID8N>K$D
M_CUIM%%48A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 48HK:\(Z+_:<XSRD>&;TX/ _'
MI^?I0.UV=]X2TS[!;HA^\PW-]6YQ^ K<INVG5)J%%%% !1110 4444 %%%%
M!1110 4444 %07=N+A6C;HP(/X\5/24 >)7EHUK(T+=48@_A_CU^E0UV?Q#T
M<JPO%Z-A6QV(Z'\1Q^ ]:XRJ1DU9A1110(**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HS110!Z_P"%
MIC-:Q,W78/TXK5K'\(?\>D7^[_4UL5)JM@HHHH&%%%% !1110 4444 %%%%
M!1110!Q'Q,Z1?\#_ )I7!5WOQ,Z1?\#_ )I7!52,Y;A11102%%%% !1110!9
MTS_6Q_[Z_P Q7M0KQ73/];'_ +Z_S%>U"DRX"T444BPHHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@!**** /#I>I^M-ITO4_6FU1B%%%% !
M1110 4444 >K^!_^/.+_ ('_ .AM6[6%X'_X\XO^!_\ H;5NU)L@HHHH ***
M* "BBB@ HHHH **** $HS145Q.(%+GH!2!)LP?$MYDB$>Q/]*P:DN)C,2YZD
MU'7G59\TFSUZ-/V<$A:***DT"BBB@ HHHH 2GVT)G8(.YIE;WAFRSF8^X']3
M5TX\\C*O4Y(.1OPVXA 4= *DQ12UZ*5CR7J%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% "8HVTM% 'F/CS2/L<WGC[DO)_P!X=?SZ
MUS->M^)](_M2!H@/F'*_4?XUY(>.#USBFC*2LPHHHIB"BBB@ HHHH *T?#^J
M?V9.LW\/1OH1@UG44 >XI)O&1WIU<QX$U7[9#Y1/S1<?4'H?Z?A73U)JG="T
M444#"BBB@ HHHH **** "BBB@!"*\A\4::=.N'C'0G<OT;M^']/>O7C7*^/=
M%-Y%YZ_?B_53U']?PIHF2T/-J*#]:*9F%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>A?#20F
M*1>PDS^8&?Y5Y[7H/PS_ -7+_OC^5#*AN=G1114F@4444 %%%% !1110 444
M4 %%%% !6#XX_P"/.7_@'_H:UO5@^./^/.7_ (!_Z&M GL>4FB@T4S(****8
M!1110 5N^!_^/R+_ ('_ .@-6%6[X'_X_(O^!_\ H#4#6YZO1114FIX71115
M&(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7ER]AU%%%=)RA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M><O_  #_ -#6MZL'QQ_QYR_\ _\ 0UH$]CRDT4&BF9!1113 **** "MWP/\
M\?D7_ __ $!JPJW? _\ Q^1?\#_] :@:W/5Z***DU/"Z***HQ"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH ***T='T";53B->.['A1^//Y=: 6I0BC,Q"J"23@ =:] \.>!A;;9Y^7'
M(7^$?7U/Z5JZ!X7CTD9'S2$<N1^@]!_/N:VRN:39HHBXI:**104444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !32G>G44 <QXI\*+J@\V/B8?DV.@
M/H?0UYK<0-;L8W!# X(/^?R]:]OQ61KWAR/6%PW#@<,.OT/J*:9$HGDE%:FL
M^'9M*/SC*]F7E?\ ZQ]CCVSUK+_STID:H**** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 )BD*YIU% 'DGBW2/[-G8
M81_F7TP3R/P-8U>F^.-(-]!O49>(EOJ/XA_(_A7F7\JI&35F%%%% @HHHH *
M*** "M[P9J_]GS@'[DHVGT'/!_/]*P:.E ;'N:G-+69X9O3>VT<IZE<'ZJ2I
M_E6G4FP4444 %%%% !1110 4444 %%%% #2*R]>T%-838PPR\JW<'_ ]Q6M3
M=N: /&=5TJ337,4HP>Q[$>H/?^?K[TZ]GU+28]10Q2KD?J/<'_.>]>=:]X+E
MT[+QY>/U Y'U'I[C\J:9FXG.T4#_ #_GM_GBBF2%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7H/PS_U<O\
MOC^5>?5Z#\,_]7+_ +X_E0RH;G9T445)H%%%% !1110 4444 %%%% !1110
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M_P!Z3_OI?_B*/^%;6_\ >D_[Z7_XBBX<AYO17I'_  K:W_O2?]]+_P#$4?\
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MY/(SS7%&*]*_X5Q;>K_FO_Q-'_"N+;U?\U_^)HN'(SS7% %>E?\ "N+;U?\
M-?\ XFG1_#NV4Y)<CT+#'Z 47#D9R'@[1VOYUDQ^[C()/;@Y'/OBO5A4%G8)
M9J(XQM4= *GI%Q5A:***!A1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !2&EI,4 >0>)=*.FS,I^ZQRI]0?\.]99..M>TW^F1WZF.50RGU_
MF#VK ?X<VQ.0SCV!7'ZJ:=R' \UHKTC_ (5O;_WI/^^E_P#B*/\ A6UO_>D_
M[Z7_ .(HN+D9YO17I'_"MK?^])_WTO\ \11_PK>W_O2?]]+_ /$47#D/-ZD@
M@:=A&H)9N@'4_P"?\FO1/^%;6_\ >D_-?_B*V=*\.P:7_JEP3_$>6_,]/PXH
MN/D)-"T_^SH$@/)4<_4DD_J:OT@&*6D6%%%% !1110 4444 %%%% !1110!Q
M>L69MY">S9(_'M5&N\GM%G&UQD>]9K>%XCT+#Z$?X5R5,/*]T=U'&144I'*Y
MHS74_P#"+1>K?F/\*/\ A%HO5OS'^%3]6F:_7*1RV:,UU/\ PBT7JWYC_"C_
M (1:+U;\Q_A1]6F'URD<M174_P#"+1>K?F/\*>GAF)>N3]3_ ( 4?5IDO&0.
M:L[)[MMBC\>PKL;*S%HNP?Y]ZEAME@&U1@5)BNBE14-3EKUW4?D+1116I@%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% ##&#7F?BOPFVGL9X@3&Q)( Y7/;Z?Y^OIU(4!HN)JYX<%S]*3%>KW
M_@NUO#N*;3ZH=OZ=/TJE_P *XMO5_P U_P#B:=R.1GFN*,5Z5_PKBV]7_-?_
M (FC_A7%MZO^:_\ Q-%PY&>:XHQ7I7_"N+;U?\U_^)H_X5Q;>K_FO_Q-%PY&
M>:XJ2"W:X81H"6;H!_*O1O\ A7%MZO\ FO\ \36KI7AJ#3.8U^;^\3D_Y^E%
MPY&3Z+I_]GPI!W1>?KU/ZU>I ,4M(T"BBB@ HHHH **** "BBB@ HHHH ***
M* $Q2; *=10!SVL>#8-1R^-C_P!Y>_U'^37'ZEX$N+3E )%_V>OY'^F:]0Q2
M;*+DN*/$9[=H#M<%3Z$8/Y&H\=Z]NGM4N!M=0P]P#_.LNX\'6D_)C /^SE?Y
M$"G<7(>2YHQ7ILGP]MFZ;Q]&']0:9_PKBV]7_-?_ (FBXN1GFN*,5Z5_PKBV
M]7_-?_B:/^%<6WJ_YK_\31<.1GFN*,5Z5_PKBV]7_-?_ (FC_A7%MZO^:_\
MQ-%PY&>:XHQ7I7_"N+;U?\U_^)H_X5Q;>K_FO_Q-%PY&>:XHQ7I7_"N+;U?\
MU_\ B:/^%<6WJ_YK_P#$T7#D9YKBC%>E?\*XMO5_S7_XFC_A7%MZO^:__$T7
M#D9YKBC%>E?\*XMO5_S7_P")H_X5Q;>K_FO_ ,31<.1GFN*,5Z5_PKBV]7_-
M?_B:/^%<6WJ_YK_\31<.1GFN*,5Z5_PKBV]7_-?_ (FC_A7%MZO^:_\ Q-%P
MY&>:XHQ7I7_"N+;U?\U_^)H_X5Q;>K_FO_Q-%PY&>:XHQ7I7_"N+;U?\U_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 21, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 21,  2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Denali Therapeutics Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-3872213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">161 Oyster Point Blvd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">866-8547<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">DNLI<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001714899<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="dnli-20260521.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="dnli-20260521.htm">dnli-20260521.htm</File>
    <File>dnli-20260521.xsd</File>
    <File>dnli-20260521_lab.xml</File>
    <File>dnli-20260521_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "dnli-20260521.htm": {
   "nsprefix": "dnli",
   "nsuri": "http://www.denalitherapeutics.com/20260521",
   "dts": {
    "inline": {
     "local": [
      "dnli-20260521.htm"
     ]
    },
    "schema": {
     "local": [
      "dnli-20260521.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "dnli-20260521_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "dnli-20260521_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 22
   },
   "report": {
    "R1": {
     "role": "http://www.denalitherapeutics.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dnli-20260521.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dnli-20260521.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001714899-26-000070-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001714899-26-000070-xbrl.zip
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M#&2BJ58"W@<GM58U:,O!/!WM$&"KH5Q$?L!Q-SZ_:@VQJZ2#O$C0OP+O=AG
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M]%#2,*:%49<#(X):P2:#I\M&G9O.-?K(G!=/C'^,EB4G<3E@.VFL/]Q&4LF
M_VZ$_K>?3429O-'VT8PTV<:A-%#?,M0+]#>+S9FNMX.[W\0 U!I6?!M&GA-
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MX3BS.OZAD^LD[^8FLV/Y.K=_&,R#*?G/:UG&/MZ.;6+\L@9#6LB+#U,;6-"
M'KV=B8=+$X_63JQN<\J;[?7PL#?PLPK#*K8]>VIG$Z7CXJ<'D4G C']/,F.2
M.)VDO=_GDP<JS\*-7\G:W52[P_F'HYG.)A" ("V*=/:$F']ELL*&.G:,9I[+
MUTXNAJ/#^8<'K27)2H/L67O1ZT4GA"2;[)9D9_0Q>@Z&H.=SFTY,HG02J5.F
MC'H_-9F>FQ);S=6[++VRD5&_SB.HJ4H3]6ZJ<Z.&@7KUZ^MC=5&4T4*E8_7\
M[.SY8#A4CT[?O!KL#AXKFZ@7.HL7W8M"3XQZIZ&[29XFWS\\& [VCW)U:G.#
MH5;HLHUF-Z'G7$<1;$DW-N/BR<X>J, 4M@DX7SSI#@[FMZ:=O=V/J<E@%S2F
M+0_WCCZ+LO X3VP!SH4?7<I1BS:#46]GAX@!CB^Q-5]F*[AIF)OY!FY&PDW\
MC%22%FIF3*%LD:MY9J%)&"Q3N0G3)*(_3!+-4YO@ZR_#QO=V9G+UQERK\W2F
M$U!U"R\_B:3WG[O/P9:(-!<:K-4X2V>J6,_PCEJU!M<VCHFYX%QADQ(,-E<F
M3N?LO-L"8B.;SG4QM>%F^?C&[L_-;L<WSZ]<%:DB*LX-DS)>T%=1&19-*=#J
M^8OCD[=OG.*#F:'.,FNRG'BL%;&5) .L?75^_K>ANM+84%+< CL_W=!_(;C!
M[O'D^/7S\[/3GU]TU&N=YSU6C8NWO[[_15T<OU$OSX_?G)Q=G+SMJ!-0?=SK
M?%9(M"H&0R>1@^'GD<BMQ %)%FHXZ# Z__+[_K+H\_-/N96[WC2?)6%//7JC
M\TC_Y_N'NP=';($?;P1PJ\\#H)T]AE6(P#R=)&F9A/ /13JGN55F\C*&7][F
M)Y2YTG&I"XK8EG%?!V/"?ER9O+ 3/))B22J?:7B161J;L(P-ON9X!8@ QD7L
MR:/8E"'M/;/A%(N8(RI4<"$\-P8E]Y) ]VU4ZCB'5RJF-P,D/76^O"/90SY-
MK_$GIO%;\- EC_D; ^B2(DS(<VR"5KH9]" PR$M G5B')DA!@ASX1^=E!L(&
M"S>6P""/?&A <E-DGD_29&RS&1Y&A)O#RH*NV#"]-DLC.[;XYG5Z9=CG C:G
M660R=9&&UA0+]6LB3VQ$V.I<6'6!T,6H1Z]/+[J_OCL]OWA,KQ3J[(R%YPP_
MPW06@ F1@KO/0+J+-8 -Y$]K4A$1M0I,8L:V$+8X<O;4BP]S*(8&GQ<JL'#$
MV26678\4F5F:Y$7&\?_W#_>&1X?][SS3G8PXTL^A.W,2Z]C+RWR:YO1_? &I
M/=S9915@0=$J-)D),CQ@2?K&<8GE/CJY>/E8Y670=5BGG!/M]1Q<_@#>% :N
M<0<+ -/@'7GB ,-?87$\:+V%2FHUGKNRX(%?3K:(>3?G.ACT'S,)3$@?Q(2:
M\B7 1 P.XC2-F %8G[K&PK%&R#2S08?81%X+;:]Z^QHB!G- %,&RKPW4JX!Z
M"2V9#5!#'89F7N@ 7,_UF&0%>QW;&)RM0"'&SBNMOQ$ ')<97LK^GT"PUQJ_
M&OQ/@)6&,6)";;(U-P8UO2^:2!&_LB8.NEGB:G33=,.7]EG#_M$_II U)V$:
M@DT6@UCD?<RU4=-T#CD<IUG'/<=!RMQE'>QLGF8%6 +FX9D9^Q.2$9:&%=&"
M^9J5">DCR2\+5D"6%^,FI!>P]="*<H[G2%IRV$^(W1C\AY2-H7KPA!U>^^ (
M&@.C<0IYT.IG2)2>0.8! D\[L(J)A3S]9D,L H-;$E6>\A>C(Y*M-Z;,TLB(
M@O*:3T D2AU!ZFNM(=_#^M93GF)"*%)3^.4(\C\AE1Z7L=\UA)96#55E?EF3
M=WCJVN7"A:CK:8HG*5MEYVP2V-K8W*D,O4 JE]F@+-CYJ[3,%&:$<H#>!-VW
M>KR>H](]P.WK)9#!"AE)70.8&83.=B7'UE$9M@DY^,/ :41I"2/9#3 ._G)N
MO,L42N.8_"&3#61RQL:(J1&C2M0T8XB1#ELY$X@9>"#D=6,2'_9&!_!G@%OF
M$V ,!+FX-D9\!IYD$[;3Y[D/^CWVY,QL<JR9"8TEO^57 FGU"X :@2:0?SLK
M9S0(5H.!+W,>2GSB8#22SWJ$):N8,(S+B$7IS^ P>123T\^T++;97YZU 3>)
MCQ'T;)((,5M,F*<%:3%4JW++#>Q 'CZ*",3QPRSA\8+$&^X\3B>+[6*^:I;O
MBX"W3.RUF VL&G"&P)4' 4O>_9KD"#;C2DBW1&*MLC0 ]E %+,E::DJ1YA,]
M/0L6(0;8<^!B $OB"@QS#,%AE!.0/#A$1<NH65K4H8PJ=#8Q1=L^OS/0974R
MM0E,<^\4X3=^-V/UVD1L;=^26N*)IG$^;>.6-4%398[/FE"$R=<$*LXHL%G=
M CJVIEE6E&F+ L&F$Y?#*EI :$$NAHE#QI\0$%/V9C@'&YI2M(7UZSQ'-%&#
M1RA[9A@BRAL.E'N\VU-P5 "NEV1.KG7&6NEQ(3QFO,@M3UY)&;MU)PCM&--1
MA($?^7B5F ^D0V:>L[%JP,Q[[W7(;DWB-(#D;>!X;<BV@,P=O1\.A[</,K]\
M\H+,;YZ3]15?"><ZU<!Q80J),IR@(*&H0BL6&DA/FN.#F"7W6E/T.8%S(1'P
M,LO@S@D,AU%5<.9"'%(ND=V&^#O!K_7#2R2 )F1[G<U#G-)*FR^S$\.U018"
M) L0I:8Z'M. P_YP7SS:\JN!89@U=Q@15N@/46IGDFAQ8_)8D?@MJ/()X C,
MI0.5$J75UNQE*<CMF(J;_(E'#8T1-5DL:"S!PT7O3U78EFKB\S1G4CW)#*)?
M (^-57)72^W7K^@@3V-@T)L4UF^U.OI1^>5J\]I2L_QWFM6Y[@FP(^SE95>/
ML<(G.H;0Y@]NN9=@#4_NQ,AM2!'D4X8@IM"6$//8LBPVTFX-M'&30(P\0AVC
M^/ GR%)-JG#S4(47*EKM(-^JT-\PUMZ_VUA[?4KZF-'31\OK?XVT_)THQ&;1
MLXQF?189J#MI)P:N&+-+.I=3T7H\-F%!*-EE>\5B7U,R! $K BR(>I(FW5E*
MZ!+>@3.50*QG!<T60@GAR+ /YTKDN7PQF\/PP@N7\)W V$5F9I1SF95Y2-E!
M*-\XP1H[G/RFWV@BOPK), #5:-++R!*H!H!;<**;<X_X6:^JFDU"1M;PV)@Y
M[;4HLX!&P4PS2GQBP=B5RV&$Z22Q3!7RQX1Q*1A\FQC$JW%,'L_%S<[1_MJ[
MD(*<!!482@WZR\]>IUD<,0')/A%,GFF7\YCJJZV5@ZV,-?G< #)3^K6B" WJ
M\*J*LG(B"#8PH2YS9ATU1%!:(#8?+-&/P;9/Z?A,%1&,AB0[2"E0VB&^F:=B
M[!C$!#&G(PKJGA,R$<) C'])T\ 16T[[UL *%(Y3O,TS0D'PD9C&%"X+MCBY
M3,!X9R(Y=N)%5RC>[;PC^?^9OL17MB#^Q3'@F8L]BHQ6X*G4K)]0]M7GP K2
MN?S3L,>7-ZGL,^[4L+P$VDNO11SR$,J8+:J@Z@95,VAWX8!BW@X#?=0XAJT@
M,X+_;Y3U3A78D73J#!,AM(' \()(D<APV8(_;2=D)!C5, U0B36Q_/:)>^JU
M6W]>@WD=AFF9R)NC[NYW1 ])A&(^$N=!=\@?0ETR'6VM0%#A6ITEE"!B,-KA
M!#+(Y<($GI8-<$;)6+<"-AH!@6K.^TKM#5O/;'[I""IJ?X,5W ,-6"]Y5>9>
MF0\4&#5D9V;(9MM\1GG&F;:5[>CXV"GW22:?^5QP:DGLMDW(1L!GE+'.R%Z0
MZ;QL5#Q-$J5U!)@O\L+,.E6@MNY;FI%D$?)?I_IG9.PR,OGB69BQS",2_IK%
MVT7P%J',W@V:!8??K0FFBG3^I+O36]. &F")-,"#9SN=46?W#J#>JXH5T2+W
M:$1@#T5KF8OAG>A$&?F=K6B]LPIAQ@@HRLQXRT>R4[UUK2$ ]"[(5LO#(R<A
M)G_,-HA",Q61>X-'*A!UYSZ-@ &Y3%K.2BK<BJQP1[K2$_BN"7[+Q<*%.A&7
M*""."LO-"L]7(RIWT:AS']+HVUR]A+1W[.LETP,KB'#SH*K$LR[%1D>N9E'
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MU*XD&3FR8WB+$&>KTM.*JSNNBQ6FWV8(CBFS%$HHPI2]MO>CU6M]S><40+H
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M   1              "  0    !D;FQI+3(P,C8P-3(Q+FAT;5!+ 0(4 Q0
M   ( #6RM5Q\H,Q%9@(  !<'   1              "  8L0  !D;FQI+3(P
M,C8P-3(Q+GAS9%!+ 0(4 Q0    ( #6RM5RCIN_V*PD  'U4   5
M      "  2 3  !D;FQI+3(P,C8P-3(Q7VQA8BYX;6Q02P$"% ,4    "  U
MLK5<S5A)EN0%  #R,   %0              @ %^'   9&YL:2TR,#(V,#4R
M,5]P<F4N>&UL4$L! A0#%     @ -;*U7)6^:@L[(   4)(  !X
M     ( !E2(  &5X.3DQ,C R-G!R97-S<F5L96%S934R,3(V+FAT;5!+!08
1    !0 % % !   ,0P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>dnli-20260521_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="dnli-20260521.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
        </entity>
        <period>
            <startDate>2026-05-21</startDate>
            <endDate>2026-05-21</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-21">0001714899</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-22">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2026-05-21</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Denali Therapeutics Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-38311</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">46-3872213</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">161 Oyster Point Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">866-8547</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">DNLI</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
